Technology
Health
Biotechnology

Recro Pharma

$8.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Recro Pharma and other stocks, options, ETFs, and crypto commission-free!

About

Recro Pharma, Inc. Common Stock, also called Recro Pharma, is a pharmaceutical company, which engages in the research and development of non-opioid therapeutics for the treatment of acute post operative pain. Read More It operates through the Acute Care, and Contract Development and Manufacturing (CDMO) business segment. The Acute Care segment focuses on developing innovative products for hospital and related settings. The CDMO segment leverages the company's formulation expertise to develop and manufacture pharmaceutical products using the company's proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Its products include Meloxicam, Dexmedetomidine, and Fadolmidine. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Malvern, PA.

Employees
260
Headquarters
Malvern, Pennsylvania
Founded
2007
Market Cap
198.98M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
297.82K
High Today
$9.01
Low Today
$8.81
Open Price
$8.99
Volume
79.58K
52 Week High
$13.05
52 Week Low
$4.78

Collections

Technology
Health
Biotechnology
Pharmaceutical
Research And Development
Therapy
Manufacturing
2014 IPO

News

Seeking AlphaMay 13

Recro Pharma, Inc. CEO Geraldine Henwood on Q1 2019 Results - Earnings Call Transcript

Recro Pharma, Inc. (NASDAQ:REPH) Q1 2019 Earnings Conference Call May 10, 2019 8:00 AM ET Company Participants Claudia Styslinger - IR Geraldine Henwood - President & CEO Ryan Lake - CFO Conference Call Participants Leland Gershell - Oppenheimer & Co. David Amsellem - Piper Jaffray Scott Henry - Roth Capital Patrick Trucchio - Berenberg Capital Market Operator Good morning, and welcome to the Recro Pharma First Quarter 2019 Financial Results Conference Call. [Operator Instructions] As a reminder,...

114
Yahoo FinanceMay 10

Recro Pharma Reports First Quarter 2019 Financial Results

Company to Host Conference Call Today at 8:00 AM ET MALVERN, Philadelphia, May 10, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today reported financial results for the three months ended March 31, 2019. “Our CDMO business is off to a strong start this year, generating $25.1 million in first quarter revenues, a 28% increase from the prior year first quarter,” ...

42
Yahoo FinanceMay 8

Recro Pharma, Inc. (REPH): Here are Midwood Capital Management’s Thoughts On The Pharmaceutical Company

Midwood Capital Management explained recent Recro Pharma (NASDAQ:REPH) stock price fluctuations in its Q1 2019 Investor Letter. If you are interested you can find a copy of the letter here. The fund also disclosed the quarterly return of 10.6%, and an annualized return since inception of 9.5%. "Recro Pharma, Inc. (REPH; $8.36; $184million market cap): We highlighted REPH in our Fourth Quarter 2018 Letter to Investors–when the stock was at $7.91 –believing that one key catalyst would be FDA approval of REPH...

42

Earnings

-$1.34
-$0.93
-$0.51
-$0.10
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$1.06 per share
Actual
-$0.10 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.